Lung Cancer
Volume 72, Issue 1 , Pages 84-91, April 2011

First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients

  • Fernanda Salazar

      Affiliations

    • Catalan Institute of Oncology, Badalona, Spain
    • ,
  • Miguel Angel Molina

      Affiliations

    • Catalan Institute of Oncology, Badalona, Spain
    • Pangaea Biotech, USP Dexeus University, Barcelona, Spain
    • ,
  • Maria Sanchez-Ronco

      Affiliations

    • University of Alcala de Henares, Madrid, Spain
    • ,
  • Teresa Moran

      Affiliations

    • Catalan Institute of Oncology, Badalona, Spain
    • ,
  • Jose Luis Ramirez

      Affiliations

    • Catalan Institute of Oncology, Badalona, Spain
    • ,
  • Jose Miguel Sanchez

      Affiliations

    • Hospital Doce de Octubre, Madrid, Spain
    • ,
  • Rolf Stahel

      Affiliations

    • Universitatsspital, Zurich, Switzerland
    • ,
  • Pilar Garrido

      Affiliations

    • Ramon y Cajal, Madrid, Spain
    • ,
  • Manuel Cobo

      Affiliations

    • Hospital Carlos Haya, Malaga, Spain
    • ,
  • Dolores Isla

      Affiliations

    • Hospital Lozano Blesa, Zaragoza, Spain
    • ,
  • Jordi Bertran-Alamillo

      Affiliations

    • Pangaea Biotech, USP Dexeus University, Barcelona, Spain
    • ,
  • Bartomeu Massuti

      Affiliations

    • Hospital General de Alicante, Alicante, Spain
    • ,
  • Felipe Cardenal

      Affiliations

    • Catalan Institute of Oncology, Hospitalet, Spain
    • ,
  • Christian Manegold

      Affiliations

    • Klinikum Mannheim der Universitat Heidelberg, Mannheim, Germany
    • ,
  • Pilar Lianes

      Affiliations

    • Hospital de Mataro, Mataro, Spain
    • ,
  • Jose Manuel Trigo

      Affiliations

    • Hospital Virgen de la Victoria, Malaga, Spain
    • ,
  • Jose Javier Sanchez

      Affiliations

    • Autonomous University of Madrid, Madrid, Spain
    • ,
  • Miquel Taron

      Affiliations

    • Catalan Institute of Oncology, Badalona, Spain
    • Pangaea Biotech, USP Dexeus University, Barcelona, Spain
    • ,
  • Rafael Rosell

      Affiliations

    • Catalan Institute of Oncology, Badalona, Spain
    • Pangaea Biotech, USP Dexeus University, Barcelona, Spain
    • Corresponding Author InformationCorresponding author at: Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Ctra Canyet, s/n, 08916 Badalona (Barcelona), Spain. Tel.: +34 93 497 89 25; fax: +34 93 497 89 50.

Received 17 May 2010; accepted 11 July 2010. published online 12 August 2010.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

PII: S0169-5002(10)00368-5

doi:10.1016/j.lungcan.2010.07.008

Lung Cancer
Volume 72, Issue 1 , Pages 84-91, April 2011

Article Tools

* Image Usage & Resolution